An open-label, randomized, parallel-group, multicenter study to compare the efficacy and safety of 'switching' to rosuvastatin 10 mg daily versus atorvastatin 10 mg daily with ezetimibe 10 mg daily versus doubling the dose of atorvastatin to 20 mg daily in subjects with hypercholesterolemia and atherosclerotic or coronary vascular disease or diabetes mellitus who have not achieved study target LDL-C [low density lipoprotein- cholesterol] goal while dosing with atorvastatin 10 mg daily

Trial Profile

An open-label, randomized, parallel-group, multicenter study to compare the efficacy and safety of 'switching' to rosuvastatin 10 mg daily versus atorvastatin 10 mg daily with ezetimibe 10 mg daily versus doubling the dose of atorvastatin to 20 mg daily in subjects with hypercholesterolemia and atherosclerotic or coronary vascular disease or diabetes mellitus who have not achieved study target LDL-C [low density lipoprotein- cholesterol] goal while dosing with atorvastatin 10 mg daily

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 15 May 2017

At a glance

  • Drugs Ezetimibe (Primary) ; Atorvastatin; Rosuvastatin
  • Indications Coronary artery disease; Diabetes mellitus; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top